Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.

Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, Motta D, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Brianese N, Quiros-Roldan E, Guaraldi G, Torti C.

HIV Clin Trials. 2012 Sep-Oct;13(5):245-55. doi: 10.1310/hct1305-245.

PMID:
23134625
[PubMed - indexed for MEDLINE]
2.

A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.

Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):18-30. doi: 10.1097/QAI.0b013e31823a6124.

PMID:
21992924
[PubMed - indexed for MEDLINE]
3.

Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.

Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, Kigozi A, Borkowf CB, Ndazima V, Brooks JT.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):304-11.

PMID:
18398971
[PubMed - indexed for MEDLINE]
4.

Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.

Casado JL, de Los Santos I, Del Palacio M, García-Fraile L, Pérez-Elías MJ, Sanz J, Moreno S.

HIV Clin Trials. 2013 Jan-Feb;14(1):1-9. doi: 10.1410/hct1401-1.

PMID:
23372109
[PubMed - indexed for MEDLINE]
5.

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.

Carey D, Amin J, Boyd M, Petoumenos K, Emery S.

J Antimicrob Chemother. 2010 Sep;65(9):1878-88. doi: 10.1093/jac/dkq231. Epub 2010 Jun 16. Review.

PMID:
20554568
[PubMed - indexed for MEDLINE]
Free Article
6.

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

Dejesus E, Mills A, Bhatti L, Conner C, Storfer S.

Int J Clin Pract. 2011 Dec;65(12):1240-9. doi: 10.1111/j.1742-1241.2011.02807.x. Epub 2011 Oct 14.

PMID:
21999631
[PubMed - indexed for MEDLINE]
7.

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.

Josephson F, Andersson MC, Flamholc L, Gisslén M, Hagberg L, Ormaasen V, Sönnerborg A, Vesterbacka J, Böttiger Y.

Eur J Clin Pharmacol. 2010 Apr;66(4):349-57. doi: 10.1007/s00228-009-0763-z. Epub 2009 Dec 5.

PMID:
19967342
[PubMed - indexed for MEDLINE]
8.

Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.

Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, Di Bari MA, Borderi M, Viale P.

Scand J Infect Dis. 2013 Feb;45(2):147-54. doi: 10.3109/00365548.2012.712213. Epub 2012 Sep 19.

PMID:
22991923
[PubMed - indexed for MEDLINE]
9.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

PMID:
18294112
[PubMed - indexed for MEDLINE]
10.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE.

J Infect Dis. 2011 Jun 15;203(12):1791-801. doi: 10.1093/infdis/jir188.

PMID:
21606537
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, Cole S, Vigen C, Cohen M, Young M, Justman J.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):34-42.

PMID:
17460470
[PubMed - indexed for MEDLINE]
12.

Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.

Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L; ARTEN investigators.

Antivir Ther. 2011;16(3):339-48. doi: 10.3851/IMP1745.

PMID:
21555816
[PubMed - indexed for MEDLINE]
13.

Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.

Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S; Japanese Anti-HIV-1 QD Therapy Study Group.

Intern Med. 2011;50(7):699-705. Epub 2011 Apr 1.

PMID:
21467701
[PubMed - indexed for MEDLINE]
Free Article
14.

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P.

PLoS Med. 2004 Oct;1(1):e19. Epub 2004 Oct 19. Erratum in: PLoS Med. 2004 Dec;1(3):e73.

PMID:
15526045
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens.

Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP.

HIV Clin Trials. 2003 Jan-Feb;4(1):29-36.

PMID:
12577194
[PubMed - indexed for MEDLINE]
16.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team.

Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

PMID:
18722869
[PubMed - indexed for MEDLINE]
17.

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D; 089 Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7.

PMID:
17971713
[PubMed - indexed for MEDLINE]
18.

Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.

Elion R, Dejesus E, Sension M, Berger D, Towner W, Richmond G, St Clair M, Yau L, Ha B; COL102060 Study Team.

HIV Clin Trials. 2008 May-Jun;9(3):152-63. doi: 10.1310/hct0903-152.

PMID:
18547902
[PubMed - indexed for MEDLINE]
19.

Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.

Tremblay C, Trottier B, Rachlis A, Baril JG, Loutfy M, Lalonde R, Sampalis JS, Boulerice F.

HIV Clin Trials. 2011 May-Jun;12(3):151-60. doi: 10.1310/hct1203-151.

PMID:
21684855
[PubMed - indexed for MEDLINE]
20.

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

Röshammar D, Simonsson US, Ekvall H, Flamholc L, Ormaasen V, Vesterbacka J, Wallmark E, Ashton M, Gisslén M.

J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):727-42. doi: 10.1007/s10928-011-9217-1. Epub 2011 Oct 2.

PMID:
21964996
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk